EVNol’s Palm Tocotrienols Found to Support Neuroprotection
07 Mar 2017 --- A new study conducted by researchers in Malaysia has shown that EVNol full spectrum palm tocotrienol-tocopherol complex aids in neuroprotection by reducing the expression of CD40, a costimulatory protein that is associated with the development of neurodegenerative diseases.
In the new study, the BV2 or microglial cells, the central nervous system-specific macrophages, were divided into unstimulated and LPS (lipopolysaccharide) stimulated groups.
Both groups were treated with EVNol 50% (full spectrum palm tocotrienol-tocopherol complex, supplied by ExcelVite) and delta-tocotrienol and followed by the addition of LPS in the LPS- stimulated group.
A chemical scavenging assay was conducted to study the nitrite scavenging activity of delta-tocotrienol.
The examination of the effects of EVNol 50% and delta-tocotrienol on the expression of CD40 on microglial cells by flow cytometry was also carried out.
The results indicated that both EVNol 50% and delta-tocotrienol exert anti-inflammatory effects by reducing expression of CD40.
Additionally, EVNol 50% showed a significant reduction in CD40 expression per microglial cell whereas delta-tocotrienol demonstrate statistically insignificant reduction.
It was also shown that delta-tocotrienol did not inhibit NO (nitrite oxide) production of microglia via nitrate scavenging.
“This is the first study to demonstrate that palm tocotrienol-tocopherol complex but not delta-tocotrienol, decreases the expression of CD40 per microglial cell effectively,” said CheeYen Lau, Nutritionist of ExcelVite.
“This suggests that the synergistic effects of full spectrum tocotrienol/tocopherol complex conferring stronger protective effects on brain health, when compared to delta-tocotrienol alone.”
“This new finding complements to the current NIH-Funded Studies at the Ohio State University, Wexner Medical Center on EVNol and EVNol SupraBio.”
“The reduction of the expression of CD40 is also correlated with reduced risks of neurodegenerative diseases such as Alzheimer’s disease, Parkinson disease and other brain-related injuries.”
The research follows other recent studies into the health benefits of EVNol, including a study suggesting that EVNol palm tocotrienol complex may aid in prostate health.
Lau added, “We are delighted to see the increasing interest from researchers in studying neuroprotective properties of EVNol and EVNol SupraBio and look forward to seeing more results, particularly human studies in the future.”
